4(1H)-quinolones having antimalarial activity with reduced chemical resistance
Provided are 4(1H)-quinolone derivatives effective in inhibiting or eliminating the viability of at least one of the stages in the life-cycle of the malarial parasite, and to show a reduced propensity to induce resistance to the compound by the target parasite. In particular, the compounds can be derivatives of phenoxyethoxy-quinolones, and including, but not only, 7-(2-phenoxyethoxy)quinolin derivatives. These compounds may be administered by themselves, with at least one other derivative compound, or with other antimalarial compounds, to an animal or human subject. The therapeutic compositions can be and formulated to reduce the extent of a Plasmodium infection in the recipient subject, or to reduce the likelihood of the onset or establishment of a Plasmodium infection if administered prior to the parasite contacting the subject. The therapeutic compositions can be formulated to provide an effective single dose amount of an antimalarial compound or multiple doses for administering over a period of time.
1. A compound having the Formula I or II:
wherein, in Formula I:
R 1 is H, ethyl, an aryl, carboxymethyl, or a halogen;
R 2 is 2-phenoxyethoxy, methoxymethoxy, 3-hydroxy-propoxy, 2-ethyl-3-oxo-butyricacid, 2-morpholino-4-yl-ethoxy-, 2-dimethylamino-ethoxy, or 3-(4-phenyl-piperazin-1-yl)-propoxy;
R 3 is H, butyrate, a halogen, methyl, or methoxy; and
R 4 is H or methyl, and wherein, when R 2 is methoxymethoxy, R 3 is a halogen; and
wherein in Formula II:
R 5 is an H or an alkyl, and
Ar is an aromatic group selected from the group consisting of: phenyl, pyridin-4-yl, pyridin-3-yl, 4-(trifluoromethyl)phenyl, 4-fluorophenoxyphenyl, 4-((4-(trifluoromethoxy)phenoxy)methyl)phenyl), (2-methyl-4-(4-(trifluoromethoxy)phenoxy)phenyl), (2-methyl-4-(trifluoromethyl)phenyl), 2,4-dimethylphenyl), (2-fluoro-4-(trifluoromethyl)phenyl), (4-chloro-2-methylphenyl), and (3,5-dimethylisooxazol-4-yl).
2. The compound of claim 1 having the Formula I.
3. A compound having the Formula I,
wherein:
R 1 is H, ethyl, an aryl, carboxymethyl, or a halogen;
R 2 is 2-phenoxyethoxy, methoxymethoxy, 3-hydroxy-propoxy, 2-ethyl-3-oxo-butyricacid, 2-morpholino-4-yl-ethoxy-, 2-dimethylamino-ethoxy, or 3-(4-phenyl-piperazin-1-yl)-propoxy;
R 3 is H, butyl, a halogen, methyl, or methoxy; and
R 4 is H or methyl, and
wherein the compound is selected from the group consisting of:
6-butyl-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one (15), 6-butyl-3-ethyl-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one (16), 6-chloro-3-ethyl-2-methyl-7-(2-phenoxy-ethoxy)-1H-quinolin-4-one (17), 3-ethyl-2,6-dimethyl-7-(2-phenoxy-ethoxy)-1H-quiolin-4-one (18), 6-chloro-3-ethyl-7-methoxymethoxy-2-methyl-1H-quinoline-4-one (20), 6-chloro-3-ethyl-7-(3-hydroxy-propoxy)-2-methyl-1H-quinolin-4-one (21), 2-ethyl-3-oxo-butyricacid-3-(6-chloro-3-ethyl-2-methyl-4-oxo-1,4-dihydro-quinolin-7-yloxy)-propyl ester (22), 6-chloro-3-ethyl-2-methyl-7-(2-morpholin-4-yl-ethoxy)-1H-quinolin-4-one (23), 6-chloro-7-(2-dimethylamino-ethoxy)-3-ethyl-2-methyl-1H-quinolin-4-one (24), 6-bromo-3-ethyl-2-methyl-7-(2-phenoxy-ethoxy)-1H-quinolin-4-one (25), and 6-chloro-3-ethyl-2-methyl-7[3-(4-phenyl-piperazin-1-yl)-propoxy]-1H-quinolin-4-one (26).
4. The compound of claim 1 having the Formula II.
5. The compound of claim 1 , wherein R 5 is methyl or ethyl.
6. The compound of claim 4 , wherein the compound is selected from the group consisting of:
6-butyl-2-methyl-7-(2-phenoxyethoxy)-3-phenylquinolin-4(1H)-one (31), 6-butyl-2-methyl-7-(2-phenoxyethoxy)-3-(pyridin-4-yl)quinolin-4(1H)-one (32), 6-butyl-2-methyl-7-(2-phenoxyethoxy)-3-(pyridin-3-yl)quinolin-4(1H)-one (33), 6-butyl-2-methyl-7-(2-phenoxyethoxy)-3-(4-(trifluoromethyl)phenyl)quinolin-4(1H)-one (34), 6-butyl-2-methyl-7-(2-phenoxyethoxy)-3-(4-(trifluoromethoxy)phenyl)quinolin-4(1H)-one (35), 6-butyl-3-(3-(4-fluorophenoxy)phenyl)-2-methyl-7-(2phenoxyethoxy)quinolin-4(1H)-one (36), 6-butyl-2-methyl-7-(2-phenoxyethoxy)-3-(4-((4-(trifluoromethoxy)phenoxy)methyl)phenyl) quinolin-4(1H)-one (37), 6-butyl-2-methyl-3-(2-methyl-4-(4-(trifluoromethoxy)phenoxy)phenyl)-7-(2-phenoxyethoxy)-quinolin-4(1H)-one (38), 6-butyl-2-methyl-3-(2-methyl-4-(trifluoromethyl)phenyl)-7-(2-phenoxyethoxy)quinolin-4(1H)-one (39), 6-butyl-3-(2,4-dimethylphenyl)-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one (40), 6-butyl-3-(2-fluoro-4-(trifluoromethyl)phenyl)-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one (41), 6-butyl-3-(4-chloro-2-methylphenyl)-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one (42), and 6-butyl-3-(3,5-dimethylisoxazol-4-yl)-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one (43).
7. A pharmaceutically acceptable composition comprising a therapeutic amount of a compound selected from the group consisting of: 6-butyl-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one (15), 6-butyl-3-ethyl-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one (16), 6-chloro-3-ethyl-2-methyl-7-(2-phenoxy-ethoxy)-1H-quinolin-4one (17), 3-ethyl-2,6-dimethyl-7-(2-phenoxy-ethoxy)-1H-quiolin-4-one (18) 6-chloro-3-ethyl-7-methoxymethoxy-2-methyl-1H-quinoline-4-one (20), 6-chloro-3-ethyl-7-(3-hydroxy-propoxy)-2-methyl-1H-quinolin-4-one (21), 2-ethyl-3-oxo-butyricacid-3-(6-chloro-3-ethyl-2-methyl-4-oxo-1,4-dihydro-quinolin-7-yloxy)-propyl ester (22), 6-chloro-3-ethyl-2-methyl-7-(2-morpholin-4-yl-ethoxy)-1H-quinolin-4-one (23), 6-chloro-7-(2-dimethylamino-ethoxy)-3-ethyl-2-methyl-1H-quinolin-4-one (24), 6-bromo-3-ethyl-2-methyl-7-(2-phenoxy-ethoxy)-1H-quinolin-4-one (25), 6-chloro-3-ethyl-2-methyl-7-[3-(4-phenyl-piperazin-1-yl)-propoxy]-1H-quinolin-4-one (26), 6-butyl-2-methyl-7-(2-phenoxyethoxy)-3-phenylquinolin-4(1H)-one (31), 6-butyl-2-methyl-7-(2-phenoxyethoxy)-3-(pyridin-4-yl)quinolin-4(1H)-one (32), 6-butyl-2-methyl-7-(2-phenoxyethoxy)-3-(pyridin-3-yl)quinolin-4(1H)-one (33), 6-butyl-2-methyl-7-(2-phenoxyethoxy)-3-(4-(trifluoromethyl)phenyl)quinolin-4(1H)-one (34), 6-butyl-2-methyl-7-(2-phenoxyethoxy)-3-(4-(trifluoromethoxy)phenyl)quinolin-4(1H)-one (35), 6-butyl-3-(3-(4-fluorophenoxy)phenyl)-2-methyl-7-(2phenoxyethoxy)quinolin-4(1H)-one (36), 6-butyl-2-methyl-7-(2-phenoxyethoxy)-3-(4-((4-(trifluoromethoxy)phenoxy)methyl)phenyl) quinolin-4(1H)-one (37), 6-butyl-2-methyl-3-(2-methyl-4-(4-(trifluoromethoxy)phenoxy)phenyl)-7-(2-phenoxyethoxy)-quinolin-4(1H)-one (38), 6-butyl-2-methyl-3-(2-methyl-4-(trifluoromethyl)phenyl)-7-(2-phenoxyethoxy)quinolin-4(1H)-one (39), 6-butyl-3-(2,4-dimethylphenyl)-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one (40), 6-butyl-3-(2-fluoro-4-(trifluoromethyl)phenyl)-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one (41), 6-butyl-3-(4-chloro-2-methylphenyl)-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one (42), and 6-butyl-3-(3,5-dimethylisoxazol-4-yl)-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one (43) that when administered to a recipient animal or human subject as a single dose or as multiple doses is effective in reducing or preventing a malarial infection in the subject.
8. The pharmaceutically acceptable composition of claim 7 , further comprising a pharmaceutically acceptable carrier.
9. A method of reducing the viability of a population of malarial parasites, wherein the method comprises administering to an animal or human subject a therapeutically effective amount of a pharmaceutically acceptable composition comprising a compound selected from the group consisting of: 6-butyl-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one (15), 6-butyl-3-ethyl-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one (16), 6-chloro-3-ethyl-2-methyl-7-(2-phenoxy-ethoxy)-1H-quinolin-4-one (17), 3-ethyl-2,6-dimethyl-7-(2-phenoxy-ethoxy)-1H-quiolin-4-one (18), 6-chloro-3-ethyl-7-methoxymethoxy-2-methyl-1H-quinoline-4-one (20), 6-chloro-3-ethyl-7-(3-hydroxy-propoxy)-2-methyl-1H-quinolin-4-one (21), 2-ethyl-3-oxo-butyricacid-3-(6-chloro-3-ethyl-2-methyl-4-oxo-1,4-dihydro-quinolin-7-yloxy)-propyl ester (22), 6-chloro-3-ethyl-2-methyl-7-(2-morpholin-4-yl-ethoxy)-1H-quinolin-4-one (23), 6-chloro-7-(2-dimethylamino-ethoxy)-3-ethyl-2-methyl-1H-quinolin-4-one (24), 6-bromo-3-ethyl-2-methyl-7-(2-phenoxy-ethoxy)-1H-quinolin-4-one (25), 6-chloro-3-ethyl-2-methyl-7-[3-(4-phenyl-piperazin-1-yl)-propoxy]-1H-quinolin-4-one (26), 6-butyl-2-methyl-7-(2-phenoxyethoxy)-3-phenylquinolin-4(1H)-one (31), 6-butyl-2-methyl-7-(2-phenoxyethoxy)-3-(pyridin-4-yl)quinolin-4(1H)-one (32), 6-butyl-2-methyl-7-(2-phenoxyethoxy)-3-(pyridin-3-yl)quinolin-4(1H)-one (33), 6-butyl-2-methyl-7-(2-phenoxyethoxy)-3-(4-(trifluoromethyl)phenyl)quinolin-4(1H)-one (34), 6-butyl-2-methyl-7-(2-phenoxyethoxy)-3-(4-(trifluoromethoxy)phenyl)quinolin-4(1H)-one (35), 6-butyl-3-(3-(4-fluorophenoxy)phenyl)-2-methyl-7-(2phenoxyethoxy)quinolin-4(1H)-one (36), 6-butyl-2-methyl-7-(2-phenoxyethoxy)-3-(4-((4-(trifluoromethoxy)phenoxy)methyl)phenyl) quinolin-4(1H)-one (37), 6-butyl-2-methyl-3-(2-methyl-4-(4-(trifluoromethoxy)phenoxy)phenyl)-7-(2-phenoxyethoxy)-quinolin-4(1H)-one (38), 6-butyl-2-methyl-3-(2-methyl-4-(trifluoromethyl)phenyl)-7-(2-phenoxyethoxy)quinolin-4(1H)-one (39), 6-butyl-3-(2,4-dimethylphenyl)-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one (40), 6-butyl-3-(2-fluoro-4-(trifluoromethyl)phenyl)-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one (41), 6-butyl-3-(4-chloro-2-methylphenyl)-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one (42), and 6-butyl-3-(3,5dimethylisoxazol-4-yl)-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one (43).
10. The method of claim 9 , wherein the compound is selected from the group consisting of:
6-butyl-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one (15), 6-butyl-3-ethyl-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one (16), 6-chloro-3-ethyl-2-methyl-7-(2-phenoxy-ethoxy)-1H-quinolin-4-one (17), 3-ethyl-2,6-dimethyl-7-(2-phenoxy-ethoxy)-1H-quiolin-4-one (18), (19), 6-chloro-3-ethyl-7-methoxymethoxy-2-methyl-1H-quinoline-4-one (20), 6-chloro-3-ethyl-7-(3-hydroxy-propoxy)-2-methyl-1H-quinolin-4-one (21), 2-ethyl-3-oxo-butyricacid-3-(6-chloro-3-ethyl-2-methyl-4-oxo-1,4-dihydro-quinolin-7-yloxy)-propyl ester (22), 6-chloro-3-ethyl-2-methyl-7-(2-morpholin-4-yl-ethoxy)-1H-quinolin-4-one (23), 6-chloro-7-(2-dimethylamino-ethoxy)-3-ethyl-2-methyl-1H-quinolin-4-one (24), 6-bromo-3-ethyl-2-methyl-7-(2-phenoxy-ethoxy)-1H-quinolin-4-one (25), and 6-chloro-3-ethyl-2-methyl-7-[3-(4-phenyl-piperazin-1-yl)-propoxy]-1H-quinolin-4-one (26).
11. The method of claim 9 , wherein the compound is selected from the group consisting of: 6-butyl-2-methyl-7-(2-phenoxyethoxy)-3-phenylquinolin-4(1H)-one (31), 6-butyl-2-methyl-7-(2-phenoxyethoxy)-3-(pyridin-4-yl)quinolin-4(1H)-one (32), 6-butyl-2-methyl-7-(2-phenoxyethoxy)-3-(pyridin-3-yl)quinolin-4(1H)-one (33), 6-butyl-2-methyl-7-(2-phenoxyethoxy)-3-(4-(trifluoromethyl)phenyl)quinolin-4(1H)-one (34), 6-butyl-2-methyl-7-(2-phenoxyethoxy)-3-(4-(trifluoromethoxy)phenyl)quinolin-4(1H)-one (35), 6-butyl-3-(3-(4-fluorophenoxy)phenyl)-2-methyl-7-(2phenoxyethoxy)quinolin-4(1H)-one (36), 6-butyl-2-methyl-7-(2-phenoxyethoxy)-3-(4-((4-(trifluoromethoxy)phenoxy)methyl)phenyl) quinolin-4(1H)-one (37), 6-butyl-2-methyl-3-(2-methyl-4-(4-(trifluoromethoxy)phenoxy)phenyl)-7-(2-phenoxyethoxy)-quinolin-4(1H)-one (38), 6-butyl-2-methyl-3-(2-methyl-4-(trifluoromethyl)phenyl)-7-(2-phenoxyethoxy)quinolin-4(1H)-one (39), 6-butyl-3-(2,4-dimethylphenyl)-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one (40), 6-butyl-3-(2-fluoro-4-(trifluoromethyl)phenyl)-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one (41), 6-butyl-3-(4-chloro-2-methylphenyl)-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one (42), and 6-butyl-3-(3,5-dimethylisoxazol-4-yl)-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one (43).